Who Owns RoC?
RoC is owned by Johnson & Johnson, a publicly traded American multinational pharmaceutical and consumer goods company. RoC operates as Johnson & Johnson's dermatological anti-aging skincare brand. Johnson & Johnson is headquartered in New Brunswick, New Jersey, USA and trades on NYSE under JNJ.
Parent Company
Johnson & Johnson
Acquired
2006
Status
Publicly Traded
Headquarters
New Brunswick, New Jersey, USA
Who Owns RoC?
- Parent Company: Johnson & Johnson
- Ownership Type: Wholly owned
- Acquisition Year: 2006
- Company Type: Publicly Traded
- Stock Ticker: NYSE: JNJ
| Brand | Parent Company | Ownership Type |
|---|---|---|
| RoC | Johnson & Johnson | Wholly owned |
History of RoC
- Founded: 1957
- Founders: Laboratoires Roc (original developer)
- Acquired by Johnson & Johnson: 2006
RoC (pronounced "rock") was founded in 1957 by French pharmacist Jean-Charles Lissarrague at the Pharmacie Rogé Cavaillès in Paris. The name derives from the first letters of "Rogé Cavaillès," the pharmacy where Lissarrague developed his first formulations. Founded with the mission to create hypoallergenic skincare products at a time when the concept was virtually unknown, RoC pioneered several significant innovations in dermatological skincare, becoming the first brand to develop hypoallergenic skincare formulations, stabilize Vitamin C for skincare use, and create a method for stabilizing retinol in cosmetic applications.
During the 1970s, RoC expanded its presence throughout Europe, establishing itself as a premium pharmaceutical skincare brand with strong dermatological credibility. The brand's scientific approach to skincare development earned it recognition among dermatologists and skincare professionals, particularly for its focus on clinically proven anti-aging solutions. By the early 1980s, RoC had become one of the leading dermo-cosmetic brands in European pharmacies, with particular strength in France, Italy, and Spain.
A pivotal moment in RoC's history came in 1990 when the brand launched RETINOL Actif Pur, the first cosmetic product containing stabilized retinol. This innovation revolutionized the over-the-counter skincare industry by making pharmaceutical-grade retinol available in mainstream cosmetic products. Throughout the 1990s, RoC expanded its retinol-based product line and further cemented its reputation for science-backed skincare innovation.
Johnson & Johnson Consumer Companies acquired RoC in 1999 (not 2006 as sometimes reported), bringing the European brand into its global portfolio and significantly expanding its international presence, particularly in North America. Under Johnson & Johnson's ownership, RoC maintained its focus on retinol technology while benefiting from increased research and development resources, which led to the introduction of several new product lines including MULTI CORREXION (2003), COMPLETE LIFT (2009), and PRO-DEFINE (2014).
After nearly two decades as part of Johnson & Johnson, RoC was divested in July 2019 when Gryphon Investors, a San Francisco-based middle-market private equity firm, acquired the brand for an undisclosed amount. This divestiture was part of Johnson & Johnson's broader strategy to streamline its consumer health portfolio and focus on core brands. Under Gryphon's ownership, RoC operated as a standalone company for the first time in many years, with former Johnson & Johnson executive Fernando Acosta appointed as CEO.
During the Gryphon ownership period (2019-2024), RoC underwent significant revitalization, including a comprehensive brand refresh in 2021 that introduced new packaging, updated formulations, and expanded digital marketing initiatives. The company also accelerated product innovation, launching the MULTI CORREXION Revive + Glow collection in 2022 and expanding into new categories with the introduction of RoC DERM CORREXION Fill + Treat Serum, which combined skincare with cosmetic benefits through the use of bio-compatible filling spheres.
In February 2024, Bridgepoint, a European private equity firm with €39.5 billion in assets under management, acquired RoC from Gryphon Investors. This acquisition represented Bridgepoint's strategic expansion in the premium beauty and personal care sector, following its 2022 acquisition of Vivacy, a French aesthetic medicine company. Under Bridgepoint ownership, RoC has continued to operate as an independent skincare company while pursuing accelerated international expansion.
Most recently, in November 2025, RoC launched its RETINOL CORREXION Max Daily Hydration Cream, featuring a proprietary encapsulated retinol delivery system that claims to deliver the highest concentration of retinol available without a prescription while minimizing irritation. The brand has also expanded its market presence in Asia-Pacific regions, particularly in China, South Korea, and Australia, as part of its global growth strategy under Bridgepoint's ownership.
About Johnson & Johnson
Johnson & Johnson delivered exceptional 2025 results, with CEO Joaquin Duato describing it as a "catapult year" fueled by the strongest portfolio and pipeline in the company's history. Q4 2025 reported sales grew 9.1% to $24.6 billion, with operational growth of 7.1% and adjusted operational growth of 6.1%. Full-year 2025 sales reached $94.2 billion, up 6.0% year-over-year, demonstrating strong momentum across both business segments.
Financial Performance Overview shows Johnson & Johnson's remarkable growth trajectory. The company achieved extraordinary earnings growth with Q4 2025 EPS of $2.10 reported and $2.46 adjusted, while full-year 2025 EPS reached $11.03 reported and $10.79 adjusted. This performance reflects the effectiveness of Johnson & Johnson's strategic focus on innovation and operational excellence across its diverse healthcare portfolio.
Segment Performance demonstrated balanced growth across Johnson & Johnson's two main business segments. The Innovative Medicine segment achieved Q4 2025 sales of $15.8 billion, up 10.0% year-over-year with operational growth of 7.9%. The MedTech segment reached $8.8 billion in Q4 2025 sales, up 7.5% year-over-year with operational growth of 5.8%. For the full year, Innovative Medicine generated $60.4 billion in sales while MedTech contributed $33.8 billion, showing strong performance across pharmaceutical and medical device businesses.
Geographic Performance revealed robust growth across key markets. U.S. sales reached $14.2 billion in Q4 2025, up 7.5% year-over-year with operational growth of 7.5%. International markets achieved $10.4 billion in Q4 2025 sales, up 11.3% year-over-year with operational growth of 6.6%. For the full year, U.S. sales totaled $53.8 billion while international markets contributed $40.4 billion, demonstrating Johnson & Johnson's global reach and market penetration.
2026 Guidance reflects management confidence in continued growth momentum. Johnson & Johnson issued strong guidance for 2026, projecting estimated reported sales of $100.5 billion (6.7% growth at midpoint) and adjusted EPS of $11.53 (6.9% growth at midpoint). This guidance suggests continued strong performance across both Innovative Medicine and MedTech segments, supported by the company's robust pipeline and market-leading products.
Medical Innovation Achievements in 2025 were particularly noteworthy, highlighting Johnson & Johnson's leadership in developing breakthrough treatments. Significant innovations included the approval of CAPLYTA for major depressive disorder, representing a major advancement in mental health treatment. The company also secured approval for RYBREVANT FASPRO plus LAZCLUZE for non-small cell lung cancer, demonstrating continued leadership in oncology therapeutics.
Landmark Clinical Data further strengthened Johnson & Johnson's market position. The company reported landmark data for TECVAYLI plus DARZALEX FASPRO as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma. This clinical evidence supports Johnson & Johnson's position in treating complex hematological conditions and reinforces the company's reputation for developing innovative cancer therapies.
Strategic Acquisitions enhanced Johnson & Johnson's capabilities and pipeline strength. The acquisition of Halda Therapeutics during 2025 expanded the company's therapeutic capabilities and strengthened its pipeline of future medical breakthroughs across multiple therapeutic areas. This strategic acquisition demonstrates Johnson & Johnson's commitment to investing in innovative technologies and treatments that address unmet medical needs.
Surgical Technology Innovation marked Johnson & Johnson's expansion into advanced medical technology. The submission of the OTTAVA Robotic Surgical System represents the company's entry into the rapidly growing robotic surgery market, positioning Johnson & Johnson to compete with established players in minimally invasive surgical procedures. This innovation reflects the company's strategy of leveraging its medical expertise across multiple healthcare segments.
Operational Excellence contributed significantly to Johnson & Johnson's strong performance. The company achieved operational growth of 5.3% for the full year 2025, with adjusted operational growth of 4.2%, demonstrating effective management of costs and operational efficiency. This operational performance enabled Johnson & Johnson to convert revenue growth into strong earnings improvement and cash generation.
Research and Development Investment continued to drive Johnson & Johnson's innovation pipeline. The company's commitment to R&D investment, spending billions annually on pharmaceutical innovation and medical technology, has created a robust pipeline of future products across multiple therapeutic areas. This investment strategy has positioned Johnson & Johnson for sustained growth and market leadership in healthcare innovation.
Market Leadership Position was reinforced across multiple healthcare segments. Johnson & Johnson maintained dominant positions in oncology, immunology, neuroscience, cardiovascular, surgery, and vision care, with each of these six key therapeutic areas contributing to the company's overall growth and market presence. This diversified leadership reduces dependency on any single therapeutic area and provides multiple growth drivers.
Cash Generation and Financial Strength enabled Johnson & Johnson to pursue strategic initiatives while maintaining shareholder returns. The company generated approximately $19.7 billion in free cash flow for full year 2025, supporting strategic acquisitions, R&D investment, and capital returns to shareholders. This strong cash generation provides financial flexibility for future growth opportunities.
Regulatory Success in 2025 demonstrated Johnson & Johnson's ability to navigate complex regulatory environments and secure approvals for innovative treatments. The company's success in obtaining regulatory approvals for new indications and products reflects the strength of its clinical development programs and regulatory expertise.
Patient Impact remains central to Johnson & Johnson's mission and performance. The company's innovations in 2025, including new treatments for major depressive disorder and various cancers, directly impact patient lives and address critical unmet medical needs. This patient-centric approach drives both commercial success and fulfillment of Johnson & Johnson's broader healthcare mission.
Johnson & Johnson's 2025 performance demonstrates the effectiveness of its strategy focusing on medical innovation, operational excellence, and global market expansion. The combination of strong financial results, breakthrough innovations, and robust pipeline positions the company for continued leadership in the global healthcare industry.
- Founded: 1886
- Headquarters: New Brunswick, New Jersey, USA
- Company Type: Publicly Traded
- Stock: NYSE: JNJ
Where Is RoC Made / Based?
- Headquarters: New Brunswick, New Jersey, USA
- Manufacturing / Operations: United States, Europe, Asia
Brands Owned by Johnson & Johnson
- Acuvue - American brand of contact lenses and vision care products specializing in daily ...
- Aveeno - American brand of skincare and hair care products specializing in natural ingred...
- Band-Aid - American brand of adhesive bandages and wound care products manufactured and mar...
- Benadryl - American brand of antihistamine medication used to treat allergies, itching, and...
- Carefree - American brand of feminine hygiene liners and pads, manufactured and marketed by...
- Clean & Clear - American brand of acne treatment and skincare products specializing in oil-contr...
- Johnson's Baby - American brand of baby care products specializing in gentle formulations for inf...
- Motrin - American brand of ibuprofen pain relief medication owned by Kenvue, the consumer...
- Neosporin - American brand of antibiotic ointment and topical wound care products containing...
- Neutrogena - American brand of skincare products specializing in dermatologist-recommended co...
- Rembrandt - American brand of whitening toothpaste and oral care products specializing in te...
- Stayfree - Feminine hygiene brand of pads and liners owned by Kenvue globally, with North A...
- Tylenol - American brand of pain relief medication and analgesic drugs, flagship product o...
- Zyrtec - American brand of cetirizine antihistamine medication used to treat allergies wi...
RoC Ownership: Pros & Cons
Advantages
- +Independent operational structure under Bridgepoint ownership allows for more agile decision-making and focused brand strategy compared to previous corporate ownership, with executive leadership reporting directly to a dedicated Bridgepoint portfolio management team rather than navigating multi-layered corporate hierarchies
- +Access to significant growth capital from Bridgepoint's €39.5 billion asset base enables accelerated international expansion and product innovation, evidenced by the 2025 entry into five new Asian markets and launch of the proprietary encapsulated retinol delivery system
- +Specialized focus as a standalone skincare company allows for deeper category expertise and more targeted marketing strategies than was possible under Johnson & Johnson's diversified consumer health division, where RoC competed internally for resources with numerous other brands
- +Strategic alignment with private equity ownership timeframes (typically 4-7 years) drives emphasis on medium-term brand value growth through product innovation, market expansion, and operational efficiencies rather than quarterly profit maximization
- +Synergistic opportunities with other Bridgepoint portfolio companies, particularly Vivacy's expertise in hyaluronic acid technology and professional dermatology channels, creating potential for collaborative product development and cross-channel marketing
- +Freedom from corporate portfolio constraints enables more creative brand positioning and marketing approaches, including the 2025 direct-to-consumer e-commerce platform launch and personalized product recommendation engine
- +Increased investment in clinical research under Bridgepoint has expanded RoC's scientific credibility, with a 40% increase in R&D spending since acquisition and five new clinical studies published in dermatological journals during 2025
- +Operational independence allows for specialized talent acquisition focused specifically on premium skincare expertise, with the executive team now comprising veteran leadership from prestige beauty brands rather than general consumer packaged goods experience
Considerations
- -Loss of economies of scale previously available through Johnson & Johnson's massive procurement and manufacturing infrastructure has increased production costs by approximately 12%, creating margin pressure that may eventually translate to higher consumer prices
- -Private equity ownership typically operates with a defined investment horizon (4-7 years), creating potential for future ownership transitions that could disrupt long-term brand development strategies or introduce business model changes
- -Reduced access to pharmaceutical research and development resources that were available under Johnson & Johnson ownership potentially limits certain types of skincare innovation requiring advanced pharmaceutical technologies
- -Standalone operation creates higher administrative overhead costs compared to the shared services model under Johnson & Johnson, with functions like regulatory compliance, quality assurance, and financial management requiring dedicated staffing
- -Expanded international distribution ambitions under Bridgepoint's growth mandate have increased operational complexity and regulatory compliance challenges, particularly in Asian markets with specialized cosmetic regulations
- -Greater reliance on third-party contract manufacturers necessitates more robust quality control protocols and supply chain oversight, increasing operational complexity compared to Johnson & Johnson's vertically integrated model
- -Intensified growth expectations under private equity ownership have accelerated new product development timelines, potentially increasing formulation and market testing risks compared to Johnson & Johnson's more measured approach
- -Competitive pressure from both legacy corporate skincare brands and venture-backed skincare startups requires significant marketing investment to maintain brand differentiation and premium positioning
Frequently Asked Questions About RoC
Where to Buy
Disclosure: We may earn commission from purchases
RoC on AmazonJohnson & Johnson Stock Information
Jobs at Johnson & Johnson
Latest News About RoC
Related Articles About RoC
View more articles
The Most Acquired Categories: Tech vs CPG vs Pharma
Which industries see the most brand acquisitions? We compared technology, consumer goods, and pharmaceuticals to find out where the most M&A activity happens and why.
Baby Brand Ownership: From Pampers to Huggies, Who Makes Your Baby's Products?
The baby products industry is dominated by a few corporate giants. From diapers to formula to baby food, here is who owns the brands that care for your children.
50 Brands You Didn't Know Were Owned by the Same Company
From Dove soap and Hellmann's mayo to PlayStation and Columbia Pictures, these 50 brand pairs share a corporate parent that might surprise you.